Meeting
2022 ASCO Annual Meeting
A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with PIK3CA-mutated/amplified and/or HRAS-overexpressing recurrent/metastatic head and neck squamous cell carcinoma.
Authors
Glenn J. Hanna
Dana-Farber Cancer Institute, Boston, MA
Glenn J. Hanna , Cesar Augusto Perez , Alan Loh Ho , Maura L. Gillison , Douglas Adkins , Ashley Dayoub , Andrew Saunders , Mollie Leoni , Stephen Dale , Kun Nie , Alex Dmitrienko
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04809233
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS6104)
DOI
10.1200/JCO.2022.40.16_suppl.TPS6104
Abstract #
TPS6104
Poster Bd #
92a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
STOPTRAFFIC-1: A phase I/II trial of SX-682 in combination with nivolumab for refractory RAS-mutated microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Benny Johnson
Poster
2014 ASCO Annual Meeting
Harvey ras (HRAS) mutations in head and neck cancer (HNC) and dependence on PI3K signaling and resistance to EGFR inhibition.
First Author: Katharina Endhardt
Poster
2024 ASCO Annual Meeting
Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study.
First Author: Alexander I. Spira
Poster
2024 ASCO Annual Meeting
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.
First Author: Cristina Saura